191 related articles for article (PubMed ID: 21227722)
1. Don't just stand there, do something: strategies for the prevention of early death in acute promyelocytic leukemia: a commentary.
Tallman MS; Manji GA
Blood Cells Mol Dis; 2011 Feb; 46(2):173-4. PubMed ID: 21227722
[No Abstract] [Full Text] [Related]
2. Sustained molecular remission in advanced acute promyelocytic leukemia with combined pulsed retinoic acid and arsenic trioxide. Clinical evidence of synergistic effect and real-time quantification of minimal residual disease.
Visani G; Piccaluga PP; Martinelli G; Rossi M; Malagola M; Baccarani M
Haematologica; 2003 Apr; 88(4):ELT15. PubMed ID: 12681992
[No Abstract] [Full Text] [Related]
3. [Treatment for acute promyelocytic leukemia].
Fujita H
Rinsho Ketsueki; 2014 Oct; 55(10):1817-26. PubMed ID: 25297745
[No Abstract] [Full Text] [Related]
4. Advances in management of acute promyelocytic leukemia with arsenic trioxide.
Ma J
Chin J Integr Med; 2007 Jun; 13(2):92-4. PubMed ID: 17609904
[No Abstract] [Full Text] [Related]
5. Arsenic trioxide for the treatment of a relapsed acute promyelocytic leukemia with acute renal failure.
Yoon HS; Park TS; Jeong KH
Pediatr Blood Cancer; 2011 Dec; 57(6):1085. PubMed ID: 21656902
[No Abstract] [Full Text] [Related]
6. A survival study and prognostic factors analysis on acute promyelocytic leukemia at a single center.
Xin L; Wan-jun S; Zeng-jun L; Yao-zhong Z; Yun-tao L; Yan L; Chang-chun W; Qiao-chuan L; Ren-chi Y; Ming-zhe H; Jian-xiang W; Lu-gui Q
Leuk Res; 2007 Jun; 31(6):765-71. PubMed ID: 17007927
[TBL] [Abstract][Full Text] [Related]
7. Updates on the treatment of acute promyelocytic leukemia.
Tallman MS
Clin Adv Hematol Oncol; 2010 Feb; 8(2):89-90. PubMed ID: 20386527
[No Abstract] [Full Text] [Related]
8. Use of all-trans retinoic acid in combination with arsenic trioxide for remission induction in patients with newly diagnosed acute promyelocytic leukemia and for consolidation/maintenance in CR patients.
Dai CW; Zhang GS; Shen JK; Zheng WL; Pei MF; Xu YX; Cao YX; Yi Y; Yang JJ; Peng HL; Zhong HY; Li RJ
Acta Haematol; 2009; 121(1):1-8. PubMed ID: 19246888
[TBL] [Abstract][Full Text] [Related]
9. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309
[TBL] [Abstract][Full Text] [Related]
10. Late first relapses in APL treated with all-trans-retinoic acid- and anthracycline- based chemotherapy: the European APL group experience (APL 91 and APL 93 trials).
Kelaidi C; Ades L; Chevret S; Sanz M; Guerci A; Thomas X; de Botton S; Raffoux E; Rayon C; Fegueux N; Bordessoule D; Rigal-Huguet F; Link H; Stoppa A; Vekhoff A; Meyer-Monard S; Castaigne S; Dombret H; Degos L; Fenaux P
Leukemia; 2006 May; 20(5):905-7. PubMed ID: 16541143
[No Abstract] [Full Text] [Related]
11. Efficacy of prolonged therapy with combined arsenic trioxide and ATRA for relapse of acute promyelocytic leukemia.
Breccia M; Cicconi L; Minotti C; Latagliata R; Giannì L; Lo-Coco F
Haematologica; 2011 Sep; 96(9):1390-1. PubMed ID: 21659361
[No Abstract] [Full Text] [Related]
12. Chemotherapy-free treatment of acute promyelocytic leukemia.
Ravandi F
Clin Adv Hematol Oncol; 2015 Aug; 13(8):498-500. PubMed ID: 26351810
[No Abstract] [Full Text] [Related]
13. Combination brings long-term remission in acute promyelocytic leukemia refractory for both all-trans retinoic acid and arsenic trioxide.
Sasaki M; Sugimoto K; Isobe Y; Oshimi K
Eur J Haematol; 2008 Aug; 81(2):160. PubMed ID: 18363868
[No Abstract] [Full Text] [Related]
14. Treatment of acute promyelocytic leukemia without cytotoxic chemotherapy.
Park JH; Tallman MS
Oncology (Williston Park); 2011 Jul; 25(8):733-41. PubMed ID: 21874835
[TBL] [Abstract][Full Text] [Related]
15. Sustained molecular remission after arsenic trioxide and gemutuzumab ozogamicin in a pediatric patient with relapsed acute promyelocytic leukemia.
Inoue A; Kawakami C; Takitani K; Tamai H
Pediatr Hematol Oncol; 2012 Mar; 29(2):170-2. PubMed ID: 22292427
[No Abstract] [Full Text] [Related]
16. Histopathological response of transitional cell carcinoma to arsenic trioxide during the treatment of concurrently diagnosed acute promyelocytic leukaemia.
Krishna R; Sorour Y; Goepel JR; Kirkbride P; Smith DJ; Ezaydi Y; Dalley CD; Snowden JA
Clin Oncol (R Coll Radiol); 2008 Dec; 20(10):769-71. PubMed ID: 18995171
[No Abstract] [Full Text] [Related]
17. Current treatment strategy of acute promyelocytic leukemia.
Mi J
Front Med; 2011 Dec; 5(4):341-7. PubMed ID: 22198746
[TBL] [Abstract][Full Text] [Related]
18. Newly diagnosed acute promyelocytic leukemia: arsenic moves front and center.
Estey EH; Hutchinson F
J Clin Oncol; 2011 Jul; 29(20):2743-6. PubMed ID: 21646610
[No Abstract] [Full Text] [Related]
19. Current management and new approaches in the treatment of APL.
Tallman MS
Clin Adv Hematol Oncol; 2003 Oct; 1(10):580-1. PubMed ID: 16258453
[No Abstract] [Full Text] [Related]
20. Clinical features and outcomes of 49 Turkish patients with acute promyelocytic leukemia who received ATRA and anthracyclines (PETHEMA protocol) therapy.
Serefhanoglu S; Buyukasik Y; Goker H; Sayinalp N; Haznedaroglu IC; Aksu S; Ozcebe OI; Turgut M; Aslan R; Ozdemir E
Leuk Res; 2010 Dec; 34(12):e317-9. PubMed ID: 20696473
[No Abstract] [Full Text] [Related]
[Next] [New Search]
